VAN ANDEL RESEARCH INSTITUTE: Form 990, tax year 2018
View the entire original 990 at ProPublica ↗
- Organization
- VAN ANDEL RESEARCH INSTITUTE (EIN 52-2000823)
- Tax period
- 2018-12-01 to 2019-11-30
- Filed
- 2020-10-09
- IRS object ID
- 202042839349301624
- Schema version
- 2018v3.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule K
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2020-10-09T15:14:31-05:00 | ReturnTs |
| Tax Period End | 2019-11-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 861065772 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | DELOITTE TAX LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 200 RENAISSANCE CENTER STE 3900 | AddressLine1Txt |
| City | DETROIT | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 48243 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2018-12-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 522000823 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | VAN ANDEL RESEARCH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | VANA | BusinessNameControlTxt |
| Phone | 6162345000 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 49503 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | TIMOTHY J MYERS | PersonNm |
| Person Title | VICE PRESIDENT & CFO | PersonTitleTxt |
| Phone | 6162345368 | PhoneNum |
| Signature | 2020-10-09 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | ANNE FULTON | PreparerPersonNm |
| PTIN | P00941863 | PTIN |
| Phone | 3133963000 | PhoneNum |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 68.48.151.109 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2020-10-09 | IPDt |
| IP Tm | 16:09:35 | IPTm |
| IP Timezone | ED | IPTimezoneCd |
| Federal Original Submission Id | 40199020202830335e01 | FederalOriginalSubmissionId |
| Federal Original Submission Id | 2020-10-09 | FederalOriginalSubmissionIdDt |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | F78548749BD4E13989256802F10A02C0F91D1746 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | F78548749BD4E13989256802F10A02C0F91D1746 | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2018 | TaxYr |
| Build TS | 2021-01-29 14:40:06Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | TIMOTHY J MYERS | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 49503 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $86,593,892 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.VAI.ORG | WebsiteAddressTxt |
| Type Of Organization Trust | Yes (X) | TypeOfOrganizationTrustInd |
| Formation | 1996 | FormationYr |
| Legal Domicile State | MI | LegalDomicileStateCd |
| Activity Or Mission | MEDICAL RESEARCH ORGANIZATION | ActivityOrMissionDesc |
| Voting Members Governing Body | 6 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 5 | VotingMembersIndependentCnt |
| Total Employee | 479 | TotalEmployeeCnt |
| Total Volunteers | 16 | TotalVolunteersCnt |
| Total Gross UBI | $1,152,917 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $193,705 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $76,050,595 | PYContributionsGrantsAmt |
| CY Contributions Grants | $74,898,909 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $1,206,439 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $1,879,646 | CYProgramServiceRevenueAmt |
| PY Investment Income | $683,062 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,317,104 | CYInvestmentIncomeAmt |
| PY Other Revenue | $8,528,787 | PYOtherRevenueAmt |
| CY Other Revenue | $8,264,369 | CYOtherRevenueAmt |
| PY Total Revenue | $86,468,883 | PYTotalRevenueAmt |
| CY Total Revenue | $86,360,028 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $1,095,983 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,433,098 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $39,942,174 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $45,621,394 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $1,082,212 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $45,167,491 | PYOtherExpensesAmt |
| CY Other Expenses | $51,587,236 | CYOtherExpensesAmt |
| PY Total Expenses | $86,205,648 | PYTotalExpensesAmt |
| CY Total Expenses | $99,641,728 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $263,235 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$13,281,700 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $229,968,935 | TotalAssetsBOYAmt |
| Total Assets EOY | $274,298,502 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $299,912,525 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $405,586,337 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | -$69,943,590 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | -$131,287,835 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | MEDICAL RESEARCH ORGANIZATION VAN ANDEL RESEARCH INSTITUTE IS AN INDEPENDENT BIOMEDICAL RESEARCH ORGANIZATION COMMITTED TO IMPROVING THE HEALTH AND ENHANCING THE LIVES OF CURRENT AND FUTURE GENERATIONS. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $12,457,371 | ExpenseAmt |
| Grant | $530,680 | GrantAmt |
| Revenue | $218,058 | RevenueAmt |
| Desc | CENTER FOR CANCER AND CELL BIOLOGY SCHEDULE O PROVIDES FURTHER INFORMATION REGARDING THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $12,490,385 | ExpenseAmt |
| Grant | $1,726,966 | GrantAmt |
| Revenue | $103,794 | RevenueAmt |
| Desc | CENTER FOR EPIGENETICSSCHEDULE O PROVIDES FURTHER INFORMATION REGARDING THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,133,555 | ExpenseAmt |
| Grant | $155,194 | GrantAmt |
| Revenue | $144,168 | RevenueAmt |
| Desc | CENTER FOR NEURODEGENERATIVE SCIENCESEE SCHEDULE O FOR FURTHER INFORMATION ABOUT THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $32,752,691 | ExpenseAmt |
| Grant | $20,258 | GrantAmt |
| Revenue | $1,413,626 | RevenueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $32,752,691 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $20,258 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $1,413,626 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $65,834,002 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (1) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | Yes (1) | TaxExemptBondsInd |
| Invest Tax Exempt Bonds | 0 | InvestTaxExemptBondsInd |
| Escrow Account | 0 | EscrowAccountInd |
| On Behalf Of Issuer | 0 | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 123 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 479 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 6 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 5 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TIMOTHY J MYERS VP & CFO | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6162345368 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 495032518 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (14 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DAVID VAN ANDEL | |||||||||
| CHAIRMAN / CEO | 36.00 | 17.00 | Yes (X) | Yes (X) | $510,007 | $0 | $112,315 | ||
| DR GEORGE VANDE WOUDE | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $8,000 | $0 | $0 | |||
| DR JAMES FAHNER | |||||||||
| TRUSTEE | 1.00 | 1.00 | Yes (X) | $8,000 | $3,000 | $0 | |||
| DR MAX WICHA | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $8,000 | $0 | $0 | |||
| DR MICHELLE LEBEAU | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $7,000 | $0 | $0 | |||
| DR TOM DEMEESTER | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $8,000 | $0 | $0 | |||
| DR JANA HALL | |||||||||
| CHIEF OPERATIONS OFFICER | 52.00 | 1.00 | Yes (X) | $457,885 | $0 | $110,728 | |||
| TIMOTHY MYERS | |||||||||
| V.P. & CHIEF FINANCIAL OFFICER | 50.00 | 3.00 | Yes (X) | $334,088 | $0 | $85,549 | |||
| DR PETER JONES | |||||||||
| CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52.00 | 1.00 | $736,084 | $0 | $168,951 | Yes (X) | |||
| KATHY VOGELSANG | |||||||||
| CHIEF INVESTMENT OFFICER | 45.00 | 0.00 | $769,994 | $0 | $288,450 | Yes (X) | |||
| DR PATRIK BRUNDIN | |||||||||
| ASSOCIATE RESEARCH DIRECTOR | 45.00 | 0.00 | $513,904 | $0 | $87,587 | Yes (X) | |||
| DR PETER LAIRD | |||||||||
| INVESTIGATOR | 45.00 | 0.00 | $410,026 | $0 | $55,027 | Yes (X) | |||
| TED HEILMAN | |||||||||
| ASSOC DIRECT-SR. PORTFOLIO MGR. | 45.00 | 0.00 | $453,788 | $0 | $179,418 | Yes (X) | |||
| DR SCOTT JEWELL | |||||||||
| DIR. PROGRAM FOR TECHNOLOGIES & CORES | 53.00 | 0.00 | $376,114 | $0 | $79,166 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,600,890 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $3,000 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $1,167,191 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 85 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| OWENS-AMES-KIMBALL CO | |||||
| 300 IONIA AVENUE NW | GRAND RAPIDS | MI | 49503 | CONSTRUCTION SERVICES | $316,630 |
| DE LAGE LANDEN FIN SVCS INC | |||||
| 1111 OLD EAGLE SCHOOL ROAD | WAYNE | PA | 19087 | EQUIPMENT LEASING | $301,452 |
| BLUE ROSE CAPITAL ADVISORS LLC | |||||
| 6400 FLYING CLOUD DR STE 212 | MINNEAPOLIS | MN | 55344 | CONSULTING SERVICES | $298,000 |
| ALLIED UNIVERSAL SECURITY | |||||
| PO BOX 828854 | PHILADELPHIA | PA | 191828854 | SECURITY SERVICES | $244,634 |
| FEDERAL EXPRESS | |||||
| PO BOX 371461 | PITTSBURGH | PA | 152512125 | SHIPPING SERVICES | $189,276 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 14 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $163,791 | FundraisingAmt |
| Related Organizations | $49,750,429 | RelatedOrganizationsAmt |
| Government Grants | $19,234,765 | GovernmentGrantsAmt |
| All Other Contributions | $5,749,924 | AllOtherContributionsAmt |
| Noncash Contributions | $26,719 | NoncashContributionsAmt |
| Total Contributions | $74,898,909 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | RESEARCH BILLED REV | Desc |
| Business | 541700 | BusinessCd |
| Total Revenue Column | $1,879,646 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $726,729 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $1,152,917 | UnrelatedBusinessRevenueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $1,879,646 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,278,111 | TotalRevenueColumnAmt |
| Exclusion | $1,278,111 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,464 | TotalRevenueColumnAmt |
| Exclusion | $3,464 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $111,078 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $112,161 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | -$1,083 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$1,083 | TotalRevenueColumnAmt |
| Exclusion | -$1,083 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $101,421 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $62,428 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $38,993 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $38,993 | TotalRevenueColumnAmt |
| Exclusion | $38,993 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $10,260 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $163,791 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $59,275 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$49,015 | TotalRevenueColumnAmt |
| Exclusion | -$49,015 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| ALLOCATED ADMIN. EXP. | 561000 | $8,040,938 | $8,040,938 |
| REIMBURSED EXPENSES | 900099 | $102,723 | $102,723 |
Miscellaneous Revenue MiscellaneousRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $167,342 | TotalRevenueColumnAmt |
| Exclusion | $167,342 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $8,311,003 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $86,360,028 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $726,729 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $1,152,917 | UnrelatedBusinessRevenueAmt |
| Exclusion | $9,581,473 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,494,431 | TotalAmt |
| Program Services | $1,494,431 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $938,667 | TotalAmt |
| Program Services | $938,667 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,229,340 | TotalAmt |
| Program Services | $767,220 | ProgramServicesAmt |
| Management And General | $1,462,120 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $34,562,207 | TotalAmt |
| Program Services | $22,300,073 | ProgramServicesAmt |
| Management And General | $11,564,759 | ManagementAndGeneralAmt |
| Fundraising | $697,375 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,894,775 | TotalAmt |
| Program Services | $1,842,351 | ProgramServicesAmt |
| Management And General | $995,005 | ManagementAndGeneralAmt |
| Fundraising | $57,419 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,817,031 | TotalAmt |
| Program Services | $2,444,193 | ProgramServicesAmt |
| Management And General | $1,321,476 | ManagementAndGeneralAmt |
| Fundraising | $51,362 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,118,041 | TotalAmt |
| Program Services | $1,333,127 | ProgramServicesAmt |
| Management And General | $718,552 | ManagementAndGeneralAmt |
| Fundraising | $66,362 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,107,317 | TotalAmt |
| Program Services | $83,553 | ProgramServicesAmt |
| Management And General | $1,023,764 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $72,791 | TotalAmt |
| Management And General | $72,791 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,000 | TotalAmt |
| Management And General | $96,000 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,963,605 | TotalAmt |
| Program Services | $2,074,204 | ProgramServicesAmt |
| Management And General | $883,036 | ManagementAndGeneralAmt |
| Fundraising | $6,365 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $853,085 | TotalAmt |
| Program Services | $384 | ProgramServicesAmt |
| Management And General | $717,261 | ManagementAndGeneralAmt |
| Fundraising | $135,440 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $174,360 | TotalAmt |
| Program Services | $50,800 | ProgramServicesAmt |
| Management And General | $123,486 | ManagementAndGeneralAmt |
| Fundraising | $74 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $326,053 | TotalAmt |
| Program Services | $140,901 | ProgramServicesAmt |
| Management And General | $176,641 | ManagementAndGeneralAmt |
| Fundraising | $8,511 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $78,255 | TotalAmt |
| Management And General | $78,255 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,743,128 | TotalAmt |
| Program Services | $2,108,470 | ProgramServicesAmt |
| Management And General | $632,558 | ManagementAndGeneralAmt |
| Fundraising | $2,100 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $890,566 | TotalAmt |
| Program Services | $627,192 | ProgramServicesAmt |
| Management And General | $229,258 | ManagementAndGeneralAmt |
| Fundraising | $34,116 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $370,209 | TotalAmt |
| Program Services | $287,106 | ProgramServicesAmt |
| Management And General | $77,827 | ManagementAndGeneralAmt |
| Fundraising | $5,276 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,876,844 | TotalAmt |
| Program Services | $6,906,334 | ProgramServicesAmt |
| Management And General | $1,970,510 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,429,828 | TotalAmt |
| Program Services | $9,856,751 | ProgramServicesAmt |
| Management And General | $1,573,077 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $548,635 | TotalAmt |
| Program Services | $347,815 | ProgramServicesAmt |
| Management And General | $200,820 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt | Program ServicesProgramServicesAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| FED / STATE INCOME TAX | $56,338 | $56,338 | ||
| LAB SUPPLIES & SERVICES | $6,389,206 | $6,389,206 | ||
| MISCELLANEOUS | $5,820,901 | $5,768,173 | $39,610 | $13,118 |
| EQUIPMENT & SOFTWARE | $3,903,931 | $1,516,635 | $2,386,071 | $1,225 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,886,184 | TotalAmt |
| Program Services | $3,415,543 | ProgramServicesAmt |
| Management And General | $1,467,172 | ManagementAndGeneralAmt |
| Fundraising | $3,469 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $99,641,728 | TotalAmt |
| Program Services | $65,834,002 | ProgramServicesAmt |
| Management And General | $32,725,514 | ManagementAndGeneralAmt |
| Fundraising | $1,082,212 | FundraisingAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,076,049 | BOYAmt |
| EOY | $5,389,037 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,270,243 | BOYAmt |
| EOY | $5,035,192 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,969,006 | BOYAmt |
| EOY | $3,713,866 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,697,944 | BOYAmt |
| EOY | $1,565,997 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $157,198 | BOYAmt |
| EOY | $261,785 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,544,611 | BOYAmt |
| EOY | $1,722,950 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $298,715,514 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $119,876,692 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $183,460,299 | BOYAmt |
| EOY | $178,838,822 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,153,585 | BOYAmt |
| EOY | $6,450,853 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $19,640,000 | BOYAmt |
| EOY | $71,320,000 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $229,968,935 | BOYAmt |
| EOY | $274,298,502 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $32,511,690 | BOYAmt |
| EOY | $90,870,304 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,256,713 | BOYAmt |
| EOY | $3,282,648 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $219,733,588 | BOYAmt |
| EOY | $219,744,537 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $45,410,534 | BOYAmt |
| EOY | $91,688,848 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $299,912,525 | BOYAmt |
| EOY | $405,586,337 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -$74,444,439 | BOYAmt |
| EOY | -$137,956,356 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,867,142 | BOYAmt |
| EOY | $5,934,614 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $633,707 | BOYAmt |
| EOY | $733,907 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -$69,943,590 | BOYAmt |
| EOY | -$131,287,835 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $229,968,935 | BOYAmt |
| EOY | $274,298,502 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$13,281,700 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $54,479 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$48,117,024 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Medical Research Organization | Yes (X) | MedicalResearchOrganizationInd |
Hospital Name And Address HospitalNameAndAddressGrp
Supported Organization Name SupportedOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SPECTRUM HEALTH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $96,000 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $96,000 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $99,545,729 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $99,641,729 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $238,376 | CurrentYearMinus3Amt |
| Current Year Minus2 | $96,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $96,000 | CurrentYearMinus1Amt |
| Current Year | $96,000 | CurrentYearAmt |
| Total | $526,376 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $626,264 | BeginningYearBalanceAmt |
| Contributions | $45,000 | ContributionsAmt |
| Investment Earnings Or Losses | $54,479 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $1,984 | OtherExpendituresAmt |
| End Year Balance | $723,759 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $666,302 | BeginningYearBalanceAmt |
| Contributions | $10,100 | ContributionsAmt |
| Investment Earnings Or Losses | $12,604 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $62,742 | OtherExpendituresAmt |
| End Year Balance | $626,264 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $612,777 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $61,326 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $7,801 | OtherExpendituresAmt |
| End Year Balance | $666,302 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributions | $596,343 | ContributionsAmt |
| Investment Earnings Or Losses | $18,408 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $1,974 | OtherExpendituresAmt |
| End Year Balance | $612,777 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 1.00000 | PrmnntEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | Yes (1) | EndowmentsHeldRelatedOrgInd |
| Related Org List Sch R | Yes (1) | RelatedOrgListSchRInd |
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,288,315 | OtherCostOrOtherBasisAmt |
| Book Value | $5,288,315 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $229,902,348 | OtherCostOrOtherBasisAmt |
| Depreciation | $72,976,644 | DepreciationAmt |
| Book Value | $156,925,704 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $62,216,522 | OtherCostOrOtherBasisAmt |
| Depreciation | $46,763,464 | DepreciationAmt |
| Book Value | $15,453,058 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,308,329 | OtherCostOrOtherBasisAmt |
| Depreciation | $136,584 | DepreciationAmt |
| Book Value | $1,171,745 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $178,838,822 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | PLEDGED SECURITIES | Desc |
| Book Value | $71,320,000 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $71,320,000 | TotalBookValueOtherAssetsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| UNREALIZED LOSS ON INTEREST RATE SWAP | $89,390,461 |
| RELATED-PARTY PAYABLE | $2,298,387 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $91,688,848 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $77,666,522 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $54,479 | NetUnrealizedGainsInvstAmt |
| Other Revenue | -$707,047 | OtherRevenueAmt |
| Revenue Not Reported | -$652,568 | RevenueNotReportedAmt |
| Revenue Subtotal | $78,319,090 | RevenueSubtotalAmt |
| Other Revenues Not Included | $8,040,938 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $8,040,938 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $86,360,028 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $139,010,767 | TotExpnsEtcAuditedFinclStmtAmt |
| Other Expenses Included | $47,409,977 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $47,409,977 | ExpensesNotReportedAmt |
| Expenses Subtotal | $91,600,790 | ExpensesSubtotalAmt |
| Other Expenses Not Included | $8,040,938 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $8,040,938 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $99,641,728 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART X, LINE 2: | PART X, LINE 1(1) AND LINE 2: THERE ARE NO UNCERTAIN TAX POSITIONS RELATED TO VARI. |
| PART XI, LINE 2D - OTHER ADJUSTMENTS: | RENTAL EXPENSES 112,161. FUNDRAISING EVENT EXPENSE 59,275. ROYALTIES PAYOUT -78,255. ADDITIONAL IMPAIRMENT -800,228. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | NET ALLOCATED 8,040,938. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | RENTAL EXPENSES 112,161. FUNDRAISING EVENT EXPENSE 59,275. LOSS ON INTEREST RATE SWAP 48,117,024. ROYALTIES PAYOUT -78,255. ADDITIONAL IMPAIRMENT -800,228. |
| PART XII, LINE 4B - OTHER ADJUSTMENTS: | NET ALLOCATED 8,040,938. |
| PART V | VAN ANDEL INSTITUTE (A RELATED ORGANIZATION) MAINTAINS ENDOWED FUNDS FOR THE BENEFIT OF BOTH VARI AND VAN ANDEL EDUCATION INSTITUTE (A RELATED ORGANIZATION) TO FUND OPERATING EXPENSES. |
| PART XI AND XII, LINE 4B | EXPENSE ALLOCATIONS PRESENTED WITHIN REVENUE. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EAST ASIA & THE PACIFIC | 0 | 1 | PROGRAM SERVICES | RESEARCH COLLABORATION - RESEARCH SERVICES | $74,971 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | RESEARCH COLLABORATION - RESEARCH SERVICES | $366,102 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | RESEARCH COLLABORATION - RESEARCH SERVICES | $40,153 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 1 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 1 | TotalEmployeeCnt |
| Subtotal Spent | $481,226 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $481,226 | TotalSpentAmt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | GRANT FUNDS ARE MONITORED BY QUARTERLY EXPENDITURE REPORTS BEFORE DISBURSING INCREMENTAL FUNDING. PROGRESS REPORTS ARE REQUIRED ANNUALLY AND REVIEWED BY VAN ANDEL RESEARCH INSTITUTE AND A THIRD PARTY. | ExplanationTxt |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | SOUTHSIDE | Event1Nm |
| Gross Receipts Event1 | $76,187 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $76,187 | CharitableContriEvent1Amt |
| Other Direct Expenses Event1 | $14,386 | OtherDirectExpensesEvent1Amt |
| Event2 | 5K RACE | Event2Nm |
| Gross Receipts Event2 | $59,791 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $49,531 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $10,260 | GrossRevenueEvent2Amt |
| Other Direct Expenses Event2 | $26,135 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 1 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $38,073 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $38,073 | CharitableContriOtherEventsAmt |
| Oth Direct Expnss Other Events | $18,754 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $174,051 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $163,791 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $10,260 | GrossRevenueTotalEventsAmt |
| Oth Direct Expnss Total Events | $59,275 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $59,275 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$49,015 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| FRIENDS OF CRESCENT PARK | |||||||
| 333 BOSTWICK NE | GRAND RAPIDS | MI | 49503 | 264562012 | 501C3 | $9,750 | SUPPORT CRESCENT PARK MAINTENANCE |
| STAND UP TO CANCER | |||||||
| 10880 WILSHIRE BLVD SUITE 1400 | LOS ANGELES | CA | 90024 | 951644609 | 501C3 | $1,484,681 | RESEARCH COLLABORATION |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 2 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (5 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Non Cash AssistanceNonCashAssistanceDesc |
|---|---|---|---|---|
| GRADUATE STUDENT STIPENDS FOR MICHIGAN STATE UNIVERSITY STUDENTS | 3 | $86,290 | ||
| GRADUATE STUDENT STIPENDS VAN ANDEL INSTITUTE GRADUATE SCHOOL | 4 | $120,666 | ||
| FOREIGN NATIONAL STIPENDS | 5 | $107,563 | ||
| GUEST STUDENT STIPENDS | 4 | $44,148 | ||
| VAN ANDEL INSTITUTE GRADUATE SCHOOL STUDENT TUITION AND FEES REMISSION | 25 | $580,000 | TUITION REMISSION. |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | STUDENTS RECEIVE A STIPEND FOR LIVING EXPENSE AND INSURANCE. GRANT FUNDS TO INSTITUTIONS ARE MONITORED BY QUARTERLY EXPENDITURE REPORTS BEFORE DISBURSING INCREMENTAL FUNDING. PROGRESS REPORTS ARE REQUIRED ANNUALLY AND REVIEWED BY VAN ANDEL RESEARCH INSTITUTE AND A THIRD PARTY. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | Yes (1) | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (9 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAVID VAN ANDEL | ||||||||||||||
| CHAIRMAN / CEO | $386,538 | $0 | $101,250 | $0 | $22,219 | $0 | $111,250 | $0 | $1,065 | $0 | $622,322 | $0 | $101,250 | $0 |
| DR JANA HALL | ||||||||||||||
| CHIEF OPERATIONS OFFICER | $358,411 | $0 | $95,900 | $0 | $3,574 | $0 | $99,609 | $0 | $11,120 | $0 | $568,614 | $0 | $95,900 | $0 |
| TIMOTHY MYERS | ||||||||||||||
| V.P. & CHIEF FINANCIAL OFFICER | $277,311 | $0 | $55,485 | $0 | $1,292 | $0 | $74,429 | $0 | $11,120 | $0 | $419,637 | $0 | $55,485 | $0 |
| DR PETER JONES | ||||||||||||||
| CHIEF SCIENTIFIC OFFICER & RES. DIR. | $562,039 | $0 | $154,092 | $0 | $19,953 | $0 | $157,832 | $0 | $11,120 | $0 | $905,036 | $0 | $154,092 | $0 |
| KATHY VOGELSANG | ||||||||||||||
| CHIEF INVESTMENT OFFICER | $415,872 | $0 | $333,300 | $0 | $20,822 | $0 | $277,330 | $0 | $11,120 | $0 | $1,058,444 | $0 | $333,300 | $0 |
| DR PATRIK BRUNDIN | ||||||||||||||
| ASSOCIATE RESEARCH DIRECTOR | $447,903 | $0 | $63,679 | $0 | $2,322 | $0 | $76,467 | $0 | $11,120 | $0 | $601,491 | $0 | $63,679 | $0 |
| DR PETER LAIRD | ||||||||||||||
| INVESTIGATOR | $387,088 | $0 | $20,611 | $0 | $2,327 | $0 | $43,907 | $0 | $11,120 | $0 | $465,053 | $0 | $20,611 | $0 |
| TED HEILMAN | ||||||||||||||
| ASSOC DIRECT-SR. PORTFOLIO MGR. | $238,565 | $0 | $194,425 | $0 | $20,798 | $0 | $168,298 | $0 | $11,120 | $0 | $633,206 | $0 | $194,425 | $0 |
| DR SCOTT JEWELL | ||||||||||||||
| DIR. PROGRAM FOR TECHNOLOGIES & CORE | $304,772 | $0 | $45,979 | $0 | $25,363 | $0 | $68,047 | $0 | $11,120 | $0 | $455,281 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | VARI ALLOWS FOR FIRST-CLASS OR CHARTER TRAVEL FOR OFFICERS AND TRUSTEES. |
| PART I, LINE 5 | BONUS IS PAID BASED ON GRANT REVENUE EARNED FOR ELIGIBLE PROGRAM PARTICIPANTS. |
Schedule K IRS990ScheduleK
Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
Issuer Name IssuerName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MICHIGAN STRATEGIC FUND | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Issuer EIN | 521417332 | BondIssuerEIN |
| CUSIP | 000000000 | CUSIPNum |
| Bond Issued | 2018-10-01 | BondIssuedDt |
| Issue Price | $220,000,000 | IssuePriceAmt |
| Purpose | REFUND BOND ISSUE 4/01/13 | PurposeDesc |
| Defeased | 0 | DefeasedInd |
| On Behalf Of Issuer | 0 | OnBehalfOfIssuerInd |
| Pool Financing | 0 | PoolFinancingInd |
Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Total Proceeds | $220,000,000 | TotalProceedsAmt |
| Other Spent Proceeds | $220,000,000 | OtherSpentProceedsAmt |
| Refunding Tax Exempt Bonds | Yes (1) | RefundingTaxExemptBondsInd |
| Refunding Taxable Bonds | 0 | RefundingTaxableBondsInd |
| Final Allocation Made | Yes (1) | FinalAllocationMadeInd |
| Adequate Books And Rec Maint | Yes (1) | AdequateBooksAndRecMaintInd |
Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Owning Bond Financed Property | 0 | OwningBondFinancedPropertyInd |
| Any Lease Arrangements | Yes (1) | AnyLeaseArrangementsInd |
| Mgmt Contract Bond Fincd Prop | Yes (1) | MgmtContractBondFincdPropInd |
| Engage Bond Counsel Contracts | Yes (1) | EngageBondCounselContractsInd |
| Any Research Agreements | Yes (1) | AnyResearchAgreementsInd |
| Engage Bond Counsel Research | Yes (1) | EngageBondCounselResearchInd |
| Private Bus Concerning UBI | 0.00440 | PrivateBusConcerningUBIPct |
| Total Private Business Use | 0.00440 | TotalPrivateBusinessUsePct |
| Bond Iss Meet Prvt Sec Pymt Test | 0 | BondIssMeetPrvtSecPymtTestInd |
| Change In Use Bond Financed Prop | 0 | ChangeInUseBondFinancedPropInd |
| Procs Nonqualified Bond Remdtd | Yes (1) | ProcsNonqualifiedBondRemdtdInd |
Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Form8038 T Filed | 0 | Form8038TFiledInd |
| Rebate Not Due Yet | Yes (1) | RebateNotDueYetInd |
| Exception To Rebate | 0 | ExceptionToRebateInd |
| No Rebate Due | 0 | NoRebateDueInd |
| Variable Rate Issue | Yes (1) | VariableRateIssueInd |
| Hedge Identified In Bks And Rec | 0 | HedgeIdentifiedInBksAndRecInd |
| Gross Proceeds Invested In GIC | 0 | GrossProceedsInvestedInGICInd |
| Gross Proceeds Invested | 0 | GrossProceedsInvestedInd |
| Written Proc To Monitor Reqs | Yes (1) | WrittenProcToMonitorReqsInd |
Procedures Corrective Action ProceduresCorrectiveActionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Procedures Corrective Action | Yes (1) | ProceduresCorrectiveActionInd |
Schedule M IRS990ScheduleM
Clothing And Household Goods ClothingAndHouseholdGoodsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Noncash Contributions Rpt F990 | $7,958 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 1 | ContributionCnt |
| Noncash Contributions Rpt F990 | $10,156 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | NYSE VALUE | MethodOfDeterminingRevenuesTxt |
Collectibles CollectiblesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 3 | ContributionCnt |
| Noncash Contributions Rpt F990 | $620 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 4 | ContributionCnt |
| Noncash Contributions Rpt F990 | $2,165 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (3 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt | Noncash Contributions Rpt F990NoncashContributionsRptF990Amt | Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt |
|---|---|---|---|---|
| Yes (X) | GIFT CARDS | 15 | $4,183 | COST |
| Yes (X) | TICKETS | 4 | $1,052 | COST |
| Yes (X) | MISCELLANEOUS | 11 | $585 | COST |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | VARI IS REPORTING THE NUMBER OF CONTRIBUTIONS RECEIVED DURING THE TAX YEAR. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (14 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 2 | VARI, VAI, VAEI, AND VAIGS SHARE COMMON MANAGEMENT. DAVID VAN ANDEL, DR. JANA HALL AND TIMOTHY MYERS ARE ALSO OFFICERS OF VAI, AND DAVID VAN ANDEL AND TIMOTHY MYERS ARE OFFICERS OF VAEI AND VAIGS. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE TRUSTEES OF VAN ANDEL INSTITUTE HAVE THE AUTHORITY TO ELECT ONE OR MORE MEMBERS OF VARI'S GOVERNING BODY. |
| FORM 990, PART VI, SECTION B, LINE 11B | FOLLOWING COMPLETION OF THE FINANCIAL STATEMENT AUDIT, THE FORM 990 IS PREPARED AND REVIEWED BY MANAGEMENT. IT IS THEN CIRCULATED TO THE FULL BOARD FOR REVIEW AND COMMENTS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | VARI HAS WRITTEN CONFLICT OF INTEREST ("COI") POLICIES AND PROCEDURES WHICH ADMINISTER AND ENFORCE A PROCESS TO IDENTIFY, EVALUATE, AND MANAGE POTENTIAL CONFLICTS OF INTEREST. THESE POLICIES HAVE BEEN APPROVED BY THE BOARD OF TRUSTEES. VAI ADMINISTERS COI POLICIES AND PROCEDURES THROUGH TWO STANDING COMMITTEES: THE CONFLICTS COMMITTEE ("CC") AND THE INSTITUTIONAL COI COMMITTEE ("ICOIC"). COI POLICIES AND PROCEDURES APPLY TO AND SERVE AS A GUIDE FOR EVERYONE IN THE ORGANIZATION. IN PARTICULAR, THEY PROVIDE A USEFUL RESOURCE FOR DEVELOPING ACTIVITIES OR RELATIONSHIPS WITH OUTSIDE ENTITIES OR PERSONS, AND ESTABLISH A PROCESS FOR COMMITTEES TO REVIEW AND MANAGE POTENTIAL CONFLICTS OF INTEREST AS THEY MAY ARISE. THE CC AND ICOIC ARE CHAIRED BY THE GENERAL COUNSEL. THE CC REQUIRES ANNUAL AND UPDATED DISCLOSURES BY COVERED PERSONS AND REVIEWS AND APPROVES MANAGEMENT PLANS. ICOIC POLICIES AND PROCEDURES SERVE AS A GUIDE FOR BOARDS OF TRUSTEES AND SENIOR EXECUTIVES. IN THE EVENT A POTENTIAL COI ARISES AT THE BOARD OR SENIOR EXECUTIVE LEVEL, THE ICOIC MEETS TO REVIEW AND DETERMINE HOW TO MANAGE SUCH A POTENTIAL CONFLICT OF INTEREST IN ACCORDANCE WITH THE COI POLICIES AND PROCEDURES. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPARABILITY DATA FROM AN EXPERT THIRD PARTY IS OBTAINED AND REVIEWED BY THE INDEPENDENT, JOINT COMPENSATION COMMITTEE OF VAN ANDEL RESEARCH INSTITUTE AND RELATED ORGANIZATIONS TO DETERMINE APPROPRIATE COMPENSATION FOR THE CEO, EXECUTIVE MANAGEMENT OFFICIALS, OFFICERS, AND KEY EMPLOYEES, ON BEHALF OF VAN ANDEL RESEARCH INSTITUTE. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL DOCUMENTS REQUIRED TO BE MADE AVAILABLE TO THE PUBLIC ARE AVAILABLE FOR PUBLIC INSPECTION UPON WRITTEN REQUEST. |
| FORM 990, PART XI, LINE 9: | LOSS ON INTEREST RATE SWAP -48,117,024. |
| FORM 990, PART III, LINE 2 | VAN ANDEL RESEARCH INSTITUTE (VARI) IS DEDICATED TO DETERMINING THE EPIGENETIC, GENETIC, MOLECULAR, AND CELLULAR ORIGINS OF CANCER, PARKINSON'S DISEASE, AND OTHER ILLNESSES AND TO TRANSLATING THOSE FINDINGS INTO EFFECTIVE THERAPIES. THE INSTITUTE'S SCIENTISTS WORK IN ON-SITE LABORATORIES AND PARTICIPATE IN COLLABORATIONS THAT SPAN THE GLOBE. WITH EPIGENETICS AS ITS COMMON THREAD, THE INSTITUTE IS ORGANIZED INTO THE CENTER FOR CANCER AND CELL BIOLOGY, THE CENTER FOR EPIGENETICS, AND THE CENTER FOR NEURODEGENERATIVE SCIENCE. THE INSTITUTE'S LABS ARE SUPPORTED BY AN OUTSTANDING CORE TECHNOLOGIES AND SERVICES GROUP, WHICH PROVIDES A VIVARIUM, A BIOREPOSITORY, AND VALUABLE ON-SITE CAPABILITIES IN IMAGING, PATHOLOGY, BIOINFORMATICS AND BIOSTATISTICS, GENOMICS, FLOW CYTOMETRY, METABOLOMICS AND BIOENERGETICS AND CRYO-ELECTRON MICROSCOPY. VARI SCIENTISTS PUBLISHED 111 ARTICLES IN THIS FISCAL YEAR IN PEER-REVIEWED JOURNALS THAT INCLUDED NATURE, SCIENCE, CELL REPORTS, NATURE COMMUNICATIONS, NATURE STRUCTURAL AND MOLECULAR BIOLOGY, SCIENCE ADVANCES, CELL REPORTS, NATURE IMMUNOLOGY, CANCER RESEARCH, IMMUNITY, CLINICAL CANCER RESEARCH, MOLECULAR NEURODEGENERATION, LANCET NEUROLOGY, NUCLEIC ACIDS RESEARCH, TRENDS IN NEUROSCIENCES, GENOME BIOLOGY, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A., CANCER CELL, THERANOSTICS, ELIFE, MOLECULAR CELL, JOURNAL OF THE NATIONAL CANCER INSTITUTE, ACTA NEUROPATHOLOGICA COMMUNICATIONS, EUROPEAN HEART JOURNAL, CIRCULATION RESEARCH, GASTROENTEROLOGY, JOURNAL OF BIOLOGICAL CHEMISTRY, NJP PARKINSON'S DISEASE, PROTEIN SCIENCE, MOLECULAR CELL, BIOCHEMISTRY, BIOINFORMATICS, CLINICAL EPIGENETICS, ISCIENCE, NEUROBIOLOGY OF DISEASE, MOLECULAR AND CELLULAR PROTEOMICS, MOLECULAR CANCER THERAPEUTICS, AND JOURNAL OF CHEMICAL THEORY AND COMPUTATION. |
| FORM 990, PART III, LINE 4A | LINE 4A - PROGRAM SERVICE ACTIVITY #1 CENTER FOR CANCER AND CELL BIOLOGY THE CENTER FOR CANCER AND CELL BIOLOGY, DIRECTED BY BART WILLIAMS, PH.D., COMPRISES 14 LABORATORIES ENGAGED IN BASIC RESEARCH IN MOLECULAR AND STRUCTURAL BIOLOGY AND IN TRANSLATIONAL RESEARCH ON CANCER, SKELETAL DISEASES, AND METABOLISM AND NUTRITION. THE CENTER IS DIVIDED INTO PROGRAMS IN STRUCTURAL BIOLOGY; SKELETAL DISEASE AND CANCER THERAPEUTICS; AND METABOLIC AND NUTRITIONAL PROGRAMMING. IN THIS FISCAL YEAR, RESEARCHERS AND TRAINEES WITHIN THE CENTER RECEIVED THREE NEW R01'S, A U01, AN R35, AND AN F31 FELLOWSHIP FROM THE NATIONAL INSTITUTES OF HEALTH. OTHER NEW AWARDS WERE FROM THE NATIONAL SCIENCE FOUNDATION, DEPARTMENT OF DEFENSE, DEPARTMENT OF ENERGY, AND THE BREAST CANCER RESEARCH FOUNDATION. TWO NEW RESEARCH CONTRACTS WERE SIGNED IN 2019, AND FOUR GRANT SUBAWARDS AND TWO NON-NIH POSTDOCTORAL FELLOWSHIPS WERE RECEIVED. IN THE STRUCTURAL BIOLOGY PROGRAM, HUILIN LI'S LAB PRODUCED SEVERAL PAPERS. THEY STUDIED THE DRS2P-CDC50P COMPLEX THAT MAINTAINS CELL MEMBRANE ASYMMETRY, SOLVING THE CRYO-EM STRUCTURES OF INTACT DRS2P-CDC50P ISOLATED FROM S. CEREVISIAE IN THE INACTIVE APO FORM AND IN THE PI4P-ACTIVATED FORM AT 2.8 ANGSTROM AND 3.3 ANGSTROM RESOLUTION, RESPECTIVELY. THIS STUDY UNCOVERED THE MECHANISM BY WHICH THE ENZYME IS ACTIVATED (BAI ET AL., NATURE COMMUNICATIONS 10: 4142). ANOTHER STUDY REPORTED THE CRYO-EM STRUCTURES OF THE S. CEREVISIAE PMT1-PMT2 COMPLEX. EACH SUBUNIT CONTAINS 11 TRANSMEMBRANE HELICES AS WELL AS A LUMENAL BETA-TREFOIL FOLD TERMED THE MIR DOMAIN. FROM THESE STRUCTURES, THE LAB WAS ABLE TO SHOW HOW THE ENZYMES RECOGNIZE THEIR SUBSTRATE MOLECULES. (BAI ET AL., NATURE STRUCTURAL AND MOLECULAR BIOLOGY 26: 704-711). A THIRD PAPER REPORTED THE STRUCTURES OF THE RV3679-RV3680 COMPLEX IN THE TUBERCULOSIS-CAUSING MYCOBACTERIUM TUBERCULOSIS. THESE PROTEINS HAVE NEVER BEEN THOROUGHLY STUDIED BEFORE, AND THIS WORK FOUND THAT THEY ARE SIMILAR TO THE UKARYOTIC GET3 AND ARSA PROTEINS. THIS PAPER THUS HAS IDENTIFIED A NEW CLASS OF BACTERIAL PROTEINS THAT HAVE FUNCTIONS WE DO NOT YET UNDERSTAND (HU ET AL., JOURNAL OF BACTERIOLOGY 201(14): E00159-19). FINALLY, THE H. LI LAB PARTICIPATED IN DEVELOPING COMPOUNDS THAT ARE POTENT INHIBITORS OF THE M. TUBERCULOSIS PROTEASOME, WHICH IS A CELLULAR COMPONENT THAT BREAKS DOWN UNNEEDED OR DAMAGED PROTEINS. THE STRUCTURE OF THE PROTEOSOME PLUS INHIBITOR SUGGESTS WHY THE INHIBITORS WORK ONLY AGAINST THE BACTERIAL PROTEOSOME BUT NOT THE HUMAN CELL PROTEOSOME. THIS KNOWLEDGE COULD AID THE DEVELOPMENT OF NEW DRUGS AGAINST TUBERCULOSIS (ZHAN ET AL., JOURNAL OF MEDICINAL CHEMISTRY 62(20): 9246-9253). STRUCTURAL RESEARCH IN THE MELCHER AND XU LABS ALSO PRODUCED SEVERAL PAPERS. ONE STUDY DEVELOPED NEW DRUG CANDIDATES AGAINST ASTHMA BASED ON STRUCTURAL ANALYSES OF THE GLUCOCORTICOID RECEPTOR (GR). ONE OF THOSE COMPOUNDS, VSG158, REPRESSED LUNG INFLAMMATION AND WAS 10 TIMES MORE POTENT IN A MOUSE MODEL THAN THE BEST GLUCOCORTICOID NOW IN CLINICAL USE, FLUTICASONE FUROATE. BOTH VSG158 AND VSG159 DELIVERED EFFECTIVE TREATMENT AND REDUCED OFF-TARGET AND SIDE EFFECTS. THEY HAVE PHARMACOKINETIC PROPERTIES THAT ARE SUITABLE FOR INHALATION TREATMENT OF ASTHMA (HE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A. 116(14): 6932-6937). THE LABS ALSO COMPLETED A STUDY ON THE HUMAN PARATHYROID HORMONE RECEPTOR-1 (PTH1R), WHICH IS A THERAPEUTIC TARGET IN OSTEOPOROSIS AND HYPOPARATHYROIDISM. THE STRUCTURE OF PTH1R BOUND TO A LONG-ACTING PTH ANALOG AND A STIMULATORY G PROTEIN WAS SOLVED. THIS RESEARCH PROVIDES INSIGHT INTO THE DYNAMICS OF PTH BINDING TO THE RECEPTOR AND RECEPTOR ACTIVATION (ZHAO ET AL., SCIENCE 364(6436): 148-153). THEY ALSO PUBLISHED A PAPER ON THE ARTHROBACTER GLOBIFORMIS URICASE ENZYME, WHICH HAS POTENTIAL AS A DRUG AGAINST HYPERURICEMIA-RELATED DISEASES. DISULFIDE BOND CROSS-LINKING PROTECTED THE ENZYME FROM DEGRADATION. SUCH INTRODUCTION OF DISULFIDE BONDS MAY BE A GENERAL AVENUE FOR IMPROVING THE STABILITY OF MANY MULTIMERIC PROTEINS, WHICH COULD IMPROVE THEIR VALUE IN MEDICAL USE (SHI ET AL., ACTA PHARMACOLOGICA SINICA 40: 1364-1372). THE LU AND DU LABS TOGETHER PUBLISHED A STUDY ON THE HUMAN TRPM2 PROTEIN, WHICH IS INVOLVED IN BODY TEMPERATURE SENSING AND IN IMMUNE RESPONSES. THEY SHOWED THE STRUCTURAL REARRANGEMENTS AND CHANNEL ACTIVATION OF TRPM2 THAT WAS INDUCED BY THE BINDING OF ADPR IN TWO SPECIFIC LOCATIONS ON THE PROTEIN, AND THAT THE ACTIVATION PROCESS DIFFERS BETWEEN THE TRPM2 PROTEINS FROM VERTEBRATES AND INVERTEBRATES. THE STUDY PROVIDES INSIGHT INTO TRPM2 ACTIVATION AND ITS PHARMACOLOGICAL PROPERTIES (HUANG ET AL., ELIFE 8: E50175). THE HAAB LAB MADE PROGRESS IN ITS WORK ON DIAGNOSTICS AND BIOMARKERS OF PANCREATIC CANCER. THEY VALIDATED THAT A GLYCAN CALLED STRA WAS A BETTER BIOMARKER OF PANCREATIC DUCTAL ADENOCARCINOMA THAN THE TRADITIONAL BIOMARKER, CA19-9. IN TWO PANELS, ONE FOR SPECIFICITY AND ONE FOR SENSITIVITY, STRA WAS STATISTICALLY BETTER THAN CA19-9 IN BOTH. THIS WORK MAY IMPROVE DIFFERENTIAL DIAGNOSIS AMONG PATIENTS WITH SUSPECTED PANCREATIC CANCER (STAAL ET AL., CLINICAL CANCER RESEARCH 25(9): 2745-2754). THE LAB ALSO DEVELOPED A NEW WAY TO ANALYZE N-GLYCOPROTEINS IN SERUM. THE ANALYSIS USES MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY IMAGING (MALDI MSI) AND ANTIBODY SLIDE ARRAYS. THIS NOVEL APPROACH CAN BE USED TO ANALYZE ANY GLYCOPROTEIN HAVING A VALIDATED ANTIBODY, AND IT CAN BE ADAPTED TO ANY BIOLOGICAL FLUID OR TISSUE SAMPLE THAT CAN BE ANALYZED BY ANTIBODY ARRAYS (BLACK ET AL., ANALYTICAL CHEMISTRY 91(13): 8429-8435). THIRD, THE LAB HAS DEVELOPED SOFTWARE CALLED SIGNALFINDER THAT USES A NEW ALGORITHM AND PERFORMS ROBUSTLY FOR THE AUTOMATED IDENTIFICATION OF MULTIPLE MARKERS IN A SINGLE SAMPLE. TWO UTILITIES PROVIDE 1) QUANTIFICATION AND MAPPING OF RELATIONSHIPS BETWEEN AN UNLIMITED NUMBER OF MARKERS AND 2) COMPOSITE PICTURES OF THE SIGNALS OR COLOCALIZATION ANALYSIS ON BRIGHTFIELD STAINED IMAGES. SIGNALFINDER ALLOWS HIGH-THROUGHPUT, RIGOROUS ANALYSES OF WHOLE-SLIDE, MULTIMARKER DATA (BARNETT ET AL., AMERICAN JOURNAL OF PATHOLOGY 189(7): 1402-1412). THE STEENSMA LAB COAUTHORED A STUDY SHOWING THAT THE KRAS G13D MUTATION OF THE RAS GTPASE ENZYME APPEARS IN 25% OF KRAS-DRIVEN COLORECTAL CANCERS, BUT THAT MUTATION IS FOUND ONLY RARELY IN HRAS OR NRAS FORMS. THE KRAS G13D DESTABILIZES THE ENZYME'S NUCLEOTIDE-BINDING POCKET. THESE RESULTS IN PART EXPLAIN THE HIGHER FREQUENCY OF THE G13D MUTANT IN KRAS OVER THE OTHER ISOFORMS OF RAS (JOHNSON ET AL., CELL REPORTS 28(6): 1538-1550.E7). THE KRAWCZYK LAB PUBLISHED A REVIEW OF THE CURRENT UNDERSTANDING OF EPIGENETIC REGULATION OF DENDRITIC CELL FUNCTION. DENDRITIC CELLS ARE A KEY PART OF THE INNATE IMMUNE SYSTEM, AND EPIGENETIC MECHANISMS CONTRIBUTE TO THE HEALTH OF DENDRITIC CELLS AND ARE IMPORTANT FOR THEIR PRECISE RESPONSE TO STIMULI. ENVIRONMENTAL FACTORS SUCH AS CHEMICALS, NUTRIENTS, AND AGING HAVE EFFECTS ON THE EPIGENOME OF DENDRITIC CELLS AND SO AFFECT THE REGULATION OF HOST IMMUNITY (BOUKHALED ET AL., FRONTIERS IN IMMUNOLOGY 10: 1119). RUSSELL JONES' LAB COAUTHORED A PAPER REPORTING ON A CONNECTION BETWEEN THE METABOLIC ACTIVITY OF IMMUNE CELLS AND DISEASE. THEY MEASURED GLYCOLYSIS AND OXYGEN CONSUMPTION RATE IN B CELLS FROM PATIENTS WHO HAD A PRIMARY ANTIBODY DEFICIENCY. THE HIGHEST OXYGEN CONSUMPTION WAS FOUND IN THREE PATIENTS WHO HAD PERSISTENT POLYCLONAL B CELL LYMPHOCYTOSIS. THE STUDY FOUND THAT MUTATIONS IN THE SDHA GENE ACTIVATED A PATHWAY THAT ENDED WITH PRODUCTION OF INFLAMMATORY CYTOKINES AND THAT BLOCKING IL-6 COULD PREVENT SYSTEMIC INFLAMMATION AND LESSEN CLINICAL DISEASE (BURGENER ET AL., NATURE IMMUNOLOGY 20(10): 1311-1321). |
| FORM 990, PART III, LINE 4B | LINE 4B - PROGRAM SERVICE ACTIVITY #2 CENTER FOR EPIGENETICS THE CENTER, ESTABLISHED IN 2014 AND DIRECTED BY ANDREW POSPISILIK, PH.D., COMPRISES 11 LABORATORIES STUDYING EPIGENETICS, EPIGENOMICS, AND THE ROLE OF EPIGENETIC DYSFUNCTION IN CANCER, NEURODEGENERATIVE DISEASE, CARDIOVASCULAR DISEASE, AND VIRAL TRANSCRIPTION. NEW GRANT AWARDS IN THIS FISCAL YEAR FOR CENTER RESEARCHERS AND TRAINEES INCLUDED TWO R01S AND AN R50 FROM THE NATIONAL INSTITUTES OF HEALTH, AS WELL AS A POSTDOCTORAL F32 AND A PRE-DOCTORAL FELLOWSHIP. TWO NIH GRANT SUB-AWARDS WERE ALSO RECEIVED. THE VAN ANDEL INSTITUTE-STAND UP TO CANCER EPIGENETICS DREAM TEAM, LED BY PETER JONES AND STEPHEN BAYLIN, CONTINUED IN 2019 WITH ITS AIMS OF DEVELOPING NEW COMBINATION THERAPIES TO COMBAT CANCER AND MOVING PROMISING THERAPIES INTO CLINICAL TRIALS. THE TEAM FOCUSES ON EPIGENETIC MECHANISMS IN CELLS, WHICH HELP CONTROL WHETHER GENES ARE TURNED ON OR OFF WITHOUT CHANGING THE DNA SEQUENCE ITSELF. THIS IS DONE PRIMARILY BY THE ADDITION OR REMOVAL OF METHYL GROUPS TO THE DNA OR ADDITION/REMOVAL OF METHYL OR ACETYL GROUPS FROM THE HISTONE PROTEINS AROUND WHICH THE DNA WRAPS. THE ROTHBART LAB REPORTED THAT THE UHRF1 PROTEIN FUNCTIONS AS A CHROMATIN READER TO MAINTAIN CANCER-SPECIFIC DNA METHYLATION IN HUMAN COLORECTAL CANCER CELLS. DISRUPTING THAT ACTIVITY REVERSES DNA HYPERMETHYLATION, REACTIVATES EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES, AND REDUCES CANCER CELL ONCOGENIC PROPERTIES. THIS RESULT SUGGESTS THE TARGETING OF THIS PROTEIN MAY BE RELEVANT IN DEVELOPING THERAPEUTIC AGENTS THAT DEMETHYLATE DNA (KONG ET AL., CANCER CELL 35(4): 633-648). THE LAB ALSO DEVELOPED A HIGH-THROUGHPUT PROTEOMICS PLATFORM THAT MAPS THE SELECTIVITY OF THE LYSINE METHYLTRANSFERASE ENZYME WITHOUT NEEDING PRIOR KNOWLEDGE OF A SUBSTRATE OR TARGET PROTEOME. THE STUDY DEMONSTRATED THE PREDICTIVE POWER OF THIS PLATFORM AND ITS USEFULNESS FOR GUIDING THE STUDY OF LYSINE METHYLATION SIGNALING (CORNETT ET AL., SCIENCE ADVANCES 4(11): EAAV2623). IN ANOTHER PAPER, THE SRA FINGER LOOP WAS IDENTIFIED AS A REGULATOR OF UHRF1 UBIQUITIN TARGETING AND OF THE MAINTENANCE OF DNA METHYLATION. THESE RESULTS PROVIDE INSIGHT INTO THE REGULATION OF UHRF1 E3 LIGASE ACTIVITY, SUGGESTING THAT ITS SRA FINGER LOOP REGULATES ITS CONFORMATION AND FUNCTION (VAUGHAN ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY 294(43): 15724-15732). PETER JONES' LAB PUBLISHED A STUDY ON CORRECTING THE VITAMIN C DEFICIENCY OF MYELOID CANCER PATIENTS. ORAL SUPPLEMENTATION LED TO AN INCREASE IN THE 5HMC/5MC RATIO RELATIVE TO PLACEBO-TREATED PATIENTS AND MAY ENHANCE THE EFFECTS OF INHIBITORS (DNMTI'S) OF METHYLTRANSFERASE ENZYMES. THE CLINICAL VALUE OF ORAL VITAMIN C SUPPLEMENTATION TO DNMTI THERAPY SHOULD BE STUDIED IN A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (GILLBERG ET AL., CLINICAL EPIGENETICS 11: 143). ANOTHER STUDY LINKED THE FREQUENCY OF IMPRINTING OF THE NC886 DIFFERENTIALLY METHYLATED REGION (DMR) IN INFANTS TO THE MOTHER'S AGE AT DELIVERY AND TO THE SEASON OF CONCEPTION. BASED ON THE RESULTS, THEY PROPOSE THAT THE IMPRINTING OF THIS DMR IS "TUNABLE" IN BEING ASSOCIATED WITH MATERNAL HAPLOTYPE AND PRENATAL ENVIRONMENT, PROVIDING A POSSIBLE MECHANISM FOR TRANSMITTING INFORMATION FROM MOTHER TO CHILD (CARPENTER ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A. 115(51): E11970-E11977). THE LAB ALSO PUBLISHED A REVIEW OF EPIGENETIC THERAPY IN IMMUNO-ONCOLOGY. INHIBITORS OF DNA METHYLATION HAVE BECOME A MAINSTAY TREATMENT FOR BLOOD CANCERS. SUCH INHIBITORS CAUSE CELLS TO MOUNT AN INNATE IMMUNE RESPONSE, AND OTHER EPIGENETIC INHIBITORS CAN PRODUCE SIMILAR EFFECTS. THESE DEVELOPMENTS OPEN NEW AVENUES FOR THE TREATMENT OF CANCERS (JONES ET AL., NATURE REVIEWS CANCER 19: 151-161). THE PFEIFER LAB QUANTIFIED DNA CYTOSINE MODIFICATIONS IN DIFFERENTIATING NEURONS ISOLATED FROM MOUSE BRAIN AT THE PEAK OF EMBRYONIC NEUROGENESIS. LOCAL DNA REGIONS HAVING LITTLE METHYLATION (HYPOMETHYLATION) WERE MUCH MORE COMMON THAN HYPERMETHYLATION. THE HYPOMETHYLATED REGIONS STRONGLY OVERLAPPED WITH THE BINDING SITES OF THE KEY NEURONAL TRANSCRIPTION FACTOR NEUROD2. THESE DATA SUGGEST A CRUCIAL ROLE FOR NEUROD2 DURING NEURON DEVELOPMENT, AND THE STUDY IS A STEP TOWARD AN EFFECTIVE APPROACH TO CONVERTING OTHER CELL TYPES INTO NEURONS FOR USE IN REGENERATIVE MEDICINE (HAHN ET AL., SCIENCE ADVANCES 5(10): EAAX0080). THE PFEIFER AND SZABO LABS PUBLISHED A STUDY IN WHICH THE CATALYTIC DOMAIN OF EITHER THE EHMT2 OR THE SETDB1 METHYLTRANSFERASE ENZYME WAS DELETED IN GROWING OOCYTES. THE DELETIONS SIGNIFICANTLY REDUCED H3K9ME2 OR H3K9ME3, RESPECTIVELY, IN THE MATERNAL PRONUCLEUS. THE ASYMMETRY OF GLOBAL 5MC OXIDATION WAS SIGNIFICANTLY LESS IN THE ZYGOTES HAVING MATERNAL MUTATION IN EHMT2 OR SETD1. THESE ENZYMES SEEM TO HAVE ROLES IN THE STRUCTURAL ASPECTS OF ZYGOTE DEVELOPMENT (ZENG ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A. 116(22): 10834-10841). A STUDY FROM THE JOVINGE LAB ON GENE EXPRESSION ANALYSIS REVEALED THAT THE MOLECULAR BEACON (MB)-POSITIVE CARDIOMYOCYTE SUBPOPULATION HAD PATTERNS CONSISTENT WITH NUCLEAR DIVISION, CHROMOSOME SEGREGATION, AND M-G1 TRANSITION. DUAL MBS TARGETING THE CDC20 AND SPG20 MRNAS ALLOWED THE IDENTIFICATION OF CYTOKINETIC EVENTS SUCH AS CDC20(HIGH)SPG20(HIGH). THIS WORK PROVIDES AN ALTERNATIVE APPROACH FOR SORTING CARDIOMYOCYTES THAT HAVE TRUE MITOTIC POTENTIAL (MILLIRON ET AL., CIRCULATION RESEARCH 125(12): 1070-1086). THE LAB ALSO EVALUATED THE SAFETY OF CROSS-SPECIES SENDAI VIRAL REPROGRAMMING OF INDUCED PLURIPOTENT STEM CELLS, AND THEY STUDIED THE DYNAMICS OF DNA TRANSCRIPTION DURING REPROGRAMMING AND DIFFERENTIATION. THIS STUDY DEMONSTRATED THE SUCCESSFUL USE OF A CLINICALLY RELEVANT METHOD TO REPROGRAM DIFFERENTIATED MOUSE CELLS AND THEIR POTENTIAL FOR GENERATING SPECIALIZED TYPES OF CARDIAC CELLS (TARNAWSKI ET AL., CELLULAR REPROGRAMMING 21(2): 78-88). A THIRD PROJECT ANALYZED CARDIAC CELLS FROM EARLY-STAGE DEVELOPING HEARTS BY USING SINGLE-CELL RNA SEQUENCING. THE DATA SHOWED HOW VARIATIONS IN CELL CYCLE ACTIVITY SELECTIVELY PROMOTE CARDIAC CHAMBER GROWTH DURING DEVELOPMENT; REVEALED CHAMBER-SPECIFIC, CELL CYCLE-LINKED TRANSCRIPTIONAL SHIFTS; AND OPEN THE WAY TO A DEEPER UNDERSTANDING OF THE ORIGINS OF CONGENITAL HEART DISEASE (LI ET AL, DEVELOPMENT 146(12): DEV173476). THE SHEN AND LAIRD LABS JOINTLY PRODUCED A SYSTEMATIC ANALYSIS OF THE EFFECTS OF SYNCHRONIZING A LARGE-SCALE, DEEPLY CHARACTERIZED, MULTI-OMIC DATA SET TO THE CURRENT HUMAN REFERENCE GENOME. THE HG19 AND HG38 CANCER GENOME ATLAS DATA SETS ARE VERY HIGHLY CONCORDANT AND PROVIDE A RUBRIC THAT ENCOURAGES SIMILAR COMPARISONS AS NEW DATA EMERGE AND AS THE REFERENCE DATA EVOLVE (GAO ET AL., CELL SYSTEMS 9(1): 24-34.E10). THEY ALSO PUBLISHED A STUDY USING DNA METHYLATION PROFILING TO DIFFERENTIATE MALIGNANT LUNG TUMORS FROM BENIGN SOLITARY PULMONARY NODULES, WHICH REQUIRES BETTER NON-INVASIVE DIAGNOSTIC TOOLS. THE RESEARCH RESULTED IN A SENSITIVE, BLOOD-BASED, NON?INVASIVE DIAGNOSTIC ASSAY FOR DETECTING EARLY-STAGE LUNG CANCER AND FOR DIFFERENTIATING LUNG CANCERS FROM BENIGN PULMONARY NODULES (LIANG ET AL., THERANOSTICS 9(7): 2056-2070). THE LAIRD LAB PRODUCED A VIDEO SHOWING HOW BOTH TIGHT REPRESSION AND ROBUST UP-REGULATION ARE POSSIBLE THROUGH REVERSIBLE, TUNABLE REMOTE-CONTROL SYSTEM THEY DEVELOPED, WHICH CAN BE APPLIED AND WITHDRAWN REPEATEDLY IN ORGANISMS. THE SYSTEM USES ENHANCED LAC REPRESSION AND TET ACTIVATION SYSTEMS TO MANIPULATE A TARGET GENE WITHIN A BIOLOGICAL SYSTEM (VANDER SCHAAF ET AL., JOURNAL OF VISUALIZED EXPERIMENTS 145). THE SHEN LAB COLLABORATED IN A STUDY OF ARID1A, A PROTEIN INVOLVED IN CHROMATIN REMODELING AND A FACTOR IN ENDOMETRIAL CANCER. THE AUTHORS PROPOSE THAT ARID1A NORMALLY MAINTAINS ENDOMETRIAL EPITHELIAL CELL IDENTITY AND THAT COEXISTENT ARID1A AND PI3K MUTATIONS PROMOTE EPITHELIAL TRANSDIFFERENTIATION AND COLLECTIVE INVASION. THESE FINDINGS SUPPORT A ROLE FOR COLLECTIVE EPITHELIAL INVASION IN THE SPREAD OF ABNORMAL ENDOMETRIAL TISSUE (WILSON ET AL., NATURE COMMUNICATIONS 10: 3554). |
| FORM 990, PART III, LINE 4B (CONT.) |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|
| FORM 990, PART III, LINE 4C | LINE 4C - PROGRAM SERVICE ACTIVITY #3 CENTER FOR NEURODEGENERATIVE SCIENCE THE CENTER WAS ESTABLISHED IN 2012 UNDER PATRIK BRUNDIN, M.D., PH.D., WHO IS ALSO ASSOCIATE DIRECTOR OF VARI. IN 2019, IT HAD NINE LABORATORIES STUDYING PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, PRIONS, AND THE RELATIONSHIPS BETWEEN DEPRESSION, SUICIDE, AND BRAIN INFLAMMATION. THE NEWEST LABORATORY, THAT OF HONG-YUAN CHU, PH.D., FOCUSES ON NEURAL CIRCUITS AND NEURODEGENERATION. CENTER RESEARCHERS AND TRAINEES DURING THIS FISCAL YEAR RECEIVED TWO R01S, TWO R21S, AND A U01 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH, AND AWARDS FROM THE FARMER FAMILY FOUNDATION, THE MICHAEL J. FOX FOUNDATION, AND THE CREUTZFELDT-JAKOB DISEASE FOUNDATION. A POSTDOCTORAL FELLOWSHIP WAS RECEIVED FROM THE AMERICAN PARKINSON DISEASE ASSOCIATION, AND TWO NEW RESEARCH CONTRACTS WERE SIGNED. THE COETZEE LAB PUBLISHED A STUDY OF 19 (OF 142) BREAST CANCER GENE RISK LOCI THAT ARE LIKELY TO FUNCTION IN THE MCF-7 BREAST CANCER CELL LINE AND ARE SUITED FOR TARGETED MANIPULATION. HOWEVER, THE RISK LOCI CANNOT BE MAPPED TO SPECIFIC CTCF BINDING SITES, AND THE GENES LINKED TO RISK SITES DID NOT SHOW FUNCTIONAL ENRICHMENT. THE IDENTITY OF THESE RISK ENHANCERS AND THEIR ASSOCIATED GENES SUGGESTS THAT SOME RISK MAY FUNCTION DURING LATER STAGES OF CANCER PROGRESSION (BOOMS ET AL., CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION 28(10): 1735-1745). THE LAB ALSO PUBLISHED A FUNCTIONAL ANALYSIS AND FINE MAPPING OF THE 9P22.2 CHROMOSOME AND ITS RELATIONSHIP TO AN OVARIAN CANCER SUSCEPTIBILITY LOCUS. THE BNC2 GENE WAS ESTABLISHED AS THE MOST LIKELY TARGET GENE. THE STUDY UNCOVERED A COMPREHENSIVE REGULATORY LANDSCAPE AT 9P22.2 AND SUGGESTS A LIKELY MECHANISM FOR AN INDIVIDUAL'S SUSCEPTIBILITY TO OVARIAN CANCER (BUCKLEY ET AL., CANCER RESEARCH 79(3): 467-481). THE PATRIK BRUNDIN AND THE MA LABS STUDIED THE "ENGRAILED1" GENE AND ITS EFFECT ON ALPHA-SYNUCLEIN AGGREGATION IN NEURONS. EN1(+/-) MICE INJECTED WITH SYNUCLEIN FIBRILS HAD A NEARLY THREEFOLD INCREASE IN SYNUCLEIN-POSITIVE NEURONS IN THE SUBSTANTIA NIGRA. THEY ALSO SHOWED SIGNIFICANT INCREASES IN THE AMYGDALA AND VENTRAL TEGMENTAL AREA AND MORE AGGREGATION IN SEVERAL CORTICAL REGIONS. THIS STUDY IS ANOTHER STEP IN DEFINING THE GENES THAT CAUSE PARKINSON'S DISEASE. (CHATTERJEE ET AL., JOURNAL OF PARKINSON'S DISEASE 9(2): 315-326). A STUDY BY THE PATRIK BRUNDIN LAB FOUND THAT THE ABSENCE OR THE HYPERSTIMULATION OF MICROGLIAL CELLS AFFECTED ALPHA-SYNUCLEIN TRANSFER IN THE MOUSE BRAIN. THE RESULTS SUGGEST THAT UNDER RESTING, NONINFLAMMATORY CONDITIONS, MICROGLIA MODULATE THE TRANSFER OF ALPHA-SYN AND THAT DRUGS WHICH REGULATE NEUROINFLAMMATION COULD BE A WAY TO LIMIT THE SPREAD OF PARKINSON'S DISEASE PATHOLOGY (GEORGE ET AL., MOLECULAR NEURODEGENERATION 14: 34). THE LABRIE LAB STUDIED 1.2 MILLION CPG AND CPH SITES IN ENHANCERS WITHIN PREFRONTAL CORTEX NEURONS AND IDENTIFIED 1224 DIFFERENTIALLY METHYLATED ENHANCER REGIONS. CPH METHYLATION LOSS, WHICH IS NORMAL IN AGING NEURONS, IS ACCELERATED IN ALZHEIMER'S DISEASE. THEY ALSO FOUND THAT NEURONS IN ALZHEIMER'S DISEASE HAVE A LARGE CLUSTER OF SIGNIFICANTLY HYPOMETHYLATED ENHANCERS IN THE DSCAML1 GENE (LI ET AL., NATURE COMMUNICATIONS 10: 2246). IN ANOTHER PROJECT, THE LAB STUDIED THE DISRUPTION OF CIRCADIAN RHYTHMS, WHICH MAY INCREASE RISK FOR MALIGNANT, PSYCHIATRIC, METABOLIC, AND OTHER DISEASES. THIS STUDY SHOWED THAT OSCILLATING CYTOSINE MODIFICATIONS (OSC-MODCS) ARE FOUND IN HUMAN NEUTROPHILS, THAT THEY MAY PLAY A ROLE IN GENE REGULATION, AND THAT THEY ARE LINKED TO COMPLEX DISEASES SUCH AS CANCER. OSC-MODCS CAN ALSO EXPLAIN PARTS OF EPIGENETIC VARIATION ARE SIGNATURES OF AGING (OH ET AL., GENOME BIOLOGY 20(1): 2). THE LABRIE AND SZAB LABS COLLABORATED ON A STUDY OF NEURONS ISOLATED FROM THE PREFRONTAL CORTEX OF PATIENTS HAVING SCHIZOPHRENIA OR BIPOLAR DISORDER. PROMINENT HYPOMETHYLATION OF AN ENHANCER OF THE IGF2 GENE WAS FOUND IN NEURONS. THAT ENHANCER TARGETS THE NEARBY TYROSINE HYDROXYLASE GENE, WHICH RESPONSIBLE FOR DOPAMINE SYNTHESIS. THE DATA SUGGEST THAT HYPOMETHYLATION ACTIVATES THE ENHANCER AT IGF2, WHICH MAY INCREASE THE DOPAMINE SYNTHESIS THAT IS ASSOCIATED WITH MAJOR PSYCHOSIS (PAI ET AL., NATURE COMMUNICATIONS 10: 2046). THE MOORE AND MA LABS PUBLISHED RESEARCH SHOWING THAT, UNLIKE PHYSIOLOGICAL ALPHA-SYNUCLEIN, DISEASE-CAUSING FORMS OF SYNUCLEIN AGGREGATES PREFERENTIALLY BIND TO MITOCHONDRIA AND AFFECT CELLULAR RESPIRATION. THIS INDICATES THAT MITOCHONDRIAL DYSFUNCTION HAS A ROLE IN ALPHA-SYNUCLEIN-RELATED DISEASES, AND IT ALSO SUGGESTS AN EXPLANATION OF THE FORMATION AND THE PECULIAR MORPHOLOGY OF LEWY BODIES (WANG ET AL., ACTA NEUROPATHOLOGICA COMMUNICATIONS 7: 41). THE MOORE, LABRIE, AND MA LABS USED A KNOCK-IN MOUSE MODEL TO SHOW THE AGE-RELATED PATHOGENIC EFFECTS OF A MUTATION IN THE VPS35 GENE IN PARKINSON'S DISEASE. THAT MODEL REPRODUCED KEY NEUROPATHOLOGICAL HALLMARKS OF PD, INCLUDING PROGRESSIVE DEGENERATION OF NIGROSTRIATAL DOPAMINERGIC NEURONS AND WIDESPREAD AXON PATHOLOGY. UNEXPECTEDLY, ENDOGENOUS D620N VPS35 EXPRESSION ALSO PRODUCED STRONG, TAU-POSITIVE, SOMATODENDRITIC PATHOLOGY THROUGHOUT THE BRAIN, WHICH RAISES THE POSSIBILITY OF INTERPLAY BETWEEN MUTANT VPS35 AND TAU IN PARKINSON'S DISEASE NEURODEGENERATION (CHEN ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A. 116(12): 5765-5774). THE MOORE LABORATORY ALSO CONTRIBUTED TO A STUDY OF RAT MODELS OF PARKINSON'S DISEASE IN ORDER TO OPTIMIZE ALPHA-SYNUCLEIN ACCUMULATION AND NIGROSTRIATAL DEGENERATION AND TO UNDERSTAND THE TIME COURSE OF BOTH PROCESSES. THE FINDINGS CAN HELP DEVELOP A REPRODUCIBLE SYNUCLEINOPATHY MODEL IN RATS THAT WOULD BE VALUABLE FOR STUDYING PATHOGENIC MECHANISMS OF PARKINSON'S DISEASE AND DISEASE-MODIFYING THERAPIES (PATTERSON ET AL., NEUROBIOLOGY OF DISEASE 130: 104525). THE LENA BRUNDIN LAB ASSAYED TRYPTOPHAN AND METABOLITE LEVELS AND THE EXPRESSION OF KYNURENINE PATHWAY ENZYMES IN PLACENTAL TISSUE FROM WOMEN WITH AND WITHOUT PRE-ECLAMPSIA. TRYPTOPHAN AND THE INFLAMMATORY MEDIATOR SAA WERE BOTH REDUCED IN PLACENTAS FROM WOMEN WITH PRE-ECLAMPSIA. THERE WAS ALSO AN INCREASED KYNURENINE/TRYPTOPHAN RATIO, BUT NO SIGNIFICANT CHANGE IN DOWNSTREAM METABOLITES (KEATON ET AL., INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH 12). ANOTHER STUDY MEASURED 45 IMMUNOBIOLOGICAL FACTORS IN PERIPHERAL BLOOD AND SHOWED THAT THE PROFILE OF PATIENTS AT INCREASED RISK OF SUICIDE DIFFERED FROM THE PROFILE ASSOCIATED WITH DEPRESSION. INCREASED INTERLEUKIN-6 AND HIGHER NUMBERS OF LYMPHOCYTES, MONOCYTES, WHITE BLOOD CELLS, AND POLYMORPHONUCLEAR LEUKOCYTES SIGNIFICANTLY AFFECTED SUICIDE RISK; THE LAST TWO HAD THE STRONGEST INFLUENCE. INTERLEUKIN-8 WAS INDEPENDENTLY AND NEGATIVELY ASSOCIATED WITH INCREASED SUICIDE RISK. THE SUICIDE RISK PROFILE INDICATED THAT GRANULOCYTE-MEDIATED BIOLOGICAL MECHANISMS COULD BE ACTIVATED IN THOSE PATIENTS (KEATON ET AL., JOURNAL OF AFFECTIVE DISORDERS 247: 57-65). THE LAB ALSO COLLABORATED ON A THIRD PAPER STUDYING BLOOD LEVELS OF INTERLEUKIN-6 (IL-6), 2-ARACHIDONOYLGLYCEROL (2-AG), AND PICOLINIC ACID (PIC) IN PERSONS HAVING A HISTORY OF MOOD, ANXIETY, OR PERSONALITY DISORDERS AND IN CONTROL SUBJECTS. THE STUDY SHOWED SIGNIFICANT ASSOCIATIONS BETWEEN IL-6 LEVEL AND PLASMA 2-AG AND PIC ACROSS ALL SUBJECTS. THE DATA PROVIDE EVIDENCE OF INTERPLAY BETWEEN THESE MOLECULES AND SUGGEST THAT THESE FACTORS INFLUENCE PERSONALITY TRAITS (HEILMAN ET AL., PSYCHONEUROENDOCRINOLOGY 110: 104434). THE GUERREIRO AND BRAS LABS PUBLISHED A STUDY OF A SEVERE, ADULT-ONSET, FAMILIAL DEGENERATIVE BRAIN DISEASE KNOWN AS HDLS-S. THEIR RECENT ASSESSMENT OF SEVERAL FAMILY MEMBERS AND DNA SEQUENCING ANALYSES SHOWED THAT THE P.CYS152PHE VARIANT IN THE AARS (ALANYL TRNA SYNTHETASE) GENE IS THE PROBABLE CAUSE OF THIS DISEASE. THE STUDY IDENTIFIES AARS AS A TARGET FOR RESEARCH INTO DEVELOPING A THERAPY FOR THIS DISEASE (SUNDAL ET AL., ACTA NEUROPATHOLOGICA COMMUNICATIONS 7: 188). |
| FORM 990, PART IX, COLUMN D | FUNDRAISING EXPENSES AT VARI WERE INCURRED TO SUPPORT THE MISSION OF THE RESEARCH INSTITUTE THROUGH DONOR SOLICITATION, GRANT SOLICITATION AND EXTRAMURAL PROPOSAL PREPARATION. |
| FORM 990, PART X, LINE 33 | VARI NET ASSETS ARE CONSIDERED ON A CONSOLIDATED BASIS WITH VAN ANDEL INSTITUTE (VAI)AND VAN ANDEL EDUCATION INSTITUTE (VAEI). ON A CONSOLIDATED BASIS, NET ASSETS ARE $1,576,560,000 PER AUDITED FINANCIAL STATEMENTS. THE NEGATIVE NET ASSET BALANCE AT VARI IS DUE TO VAI FUNDING EXPENSES ON A CASH BASIS AND THE UNREALIZED LOSS RECORDED IN ASSOCIATION WITH THE INTEREST RATE SWAP. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|
| VAI INNOVATIONS LLC | |||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000823 | LICENSING INTELLECTUAL PROPERTY OF VARI | MI | $0 | $0 | VAN ANDEL RESEARCH INSTITUTE |
| BOSTWICK EVENT MANAGEMENT | |||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000823 | EVENT MANAGEMENT | MI | $34,867 | $118,738 | VAN ANDEL RESEARCH INSTITUTE |
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Direct Controlling NADirectControllingNACd | Controlled OrganizationControlledOrganizationInd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VAN ANDEL INSTITUTE | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000820 | SUPPORTING ORGANIZATION FOR VARI AND VAEI | MI | 501(C)(3) | 12C | N/A | 0 | |
| VAN ANDEL EDUCATION INSTITUTE | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000824 | OPERATING A SCIENCE EDUCATION PROGRAM | MI | 501(C)(3) | 2 | Yes (1) | VAN ANDEL INSTITUTE | |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | ME | 495032518 | 203340886 | OPERATING A GRADUATE SCHOOL | MI | 501(C)(3) | 2 | Yes (1) | VAN ANDEL EDUCATION INSTITUTE | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | Yes (1) | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (1) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (1) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | Yes (1) | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | Yes (1) | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (20 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| VAN ANDEL INSTITUTE | ||
| C | $49,750,429 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE | ||
| E | $71,320,000 | TOTAL RECORDED |
| VAN ANDEL INSTITUTE | ||
| N | $287,419 | ALLOCATION BASED ON SQ. FOOTAGE |
| VAN ANDEL INSTITUTE | ||
| P | $1,210,302 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE | ||
| N | $198,021 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| O | $1,132,338 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| P | $613,371 | ACTUAL AMOUNT PAID |
| VAN ANDEL EDUCATION INSTITUTE | ||
| Q | $1,826,197 | ACTUAL AMOUNT RECEIVED |
| VAN ANDEL EDUCATION INSTITUTE | ||
| N | $49,968 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| O | $285,730 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| N | $24,059 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| N | $161,673 | ALLOCATION BASED ON SQ. FOOTAGE |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| Q | $240,798 | ACTUAL AMOUNT RECEIVED |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| O | $137,574 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| Q | $7,023,320 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE | ||
| E | $4,137,107 | TOTAL RECORDED |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| P | $580,000 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| O | $135,811 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| O | $135,811 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| O | $85,418 | ALLOCATION BASED ON EFFORT |